Cancer Research UK programme grant (C8162/A16892). Smith is supported by a Cancer Research UK Postdoctoral fellowship (C42785/A17965). FMW is funded by an NIHR Clinician Scientist award (RG 68235)
Abstract Background The Cytosponge is a cell-collection device, which, coupled with a test for trefo...
Barrett's esophagus (BE) is a commonly undiagnosed condition that predisposes to esophageal adenocar...
In the Perspective article in the March issue of Cellular and Molecular Gastroenterology and Hepatol...
Objective: To investigate the acceptability of the Cytosponge, a novel sampling device to detect Bar...
OBJECTIVE: To investigate the acceptability of the Cytosponge, a novel sampling device to detect Bar...
Objectives: The BEST3 trial demonstrated the efficacy and safety of the Cytosponge-trefoil factor 3,...
BACKGROUND: Treatment of dysplastic Barrett's oesophagus prevents progression to adenocarcinoma; how...
Background: Early detection of oesophageal cancer improves outcomes; however, the optimal strategy f...
BACKGROUND & AIMS: Diagnosis and surveillance of Barrett's esophagus (BE) and eosinophilic esophagit...
BACKGROUND: Early detection of oesophageal cancer improves outcomes; however, the optimal strategy f...
This multicentre, pragmatic, randomised controlled trial was done in 109 socio-demographically diver...
Background: Esophageal adenocarcinoma (EAC) accounts for an estimated 15 690 deaths in the US each y...
BACKGROUND: Barrett's esophagus (BE) is a commonly undiagnosed condition that predisposes to esophag...
Barrett's esophagus (BE) is a commonly undiagnosed condition that predisposes to esophageal adenocar...
BACKGROUND: Barrett's oesophagus predisposes to adenocarcinoma. However, most patients with Barrett'...
Abstract Background The Cytosponge is a cell-collection device, which, coupled with a test for trefo...
Barrett's esophagus (BE) is a commonly undiagnosed condition that predisposes to esophageal adenocar...
In the Perspective article in the March issue of Cellular and Molecular Gastroenterology and Hepatol...
Objective: To investigate the acceptability of the Cytosponge, a novel sampling device to detect Bar...
OBJECTIVE: To investigate the acceptability of the Cytosponge, a novel sampling device to detect Bar...
Objectives: The BEST3 trial demonstrated the efficacy and safety of the Cytosponge-trefoil factor 3,...
BACKGROUND: Treatment of dysplastic Barrett's oesophagus prevents progression to adenocarcinoma; how...
Background: Early detection of oesophageal cancer improves outcomes; however, the optimal strategy f...
BACKGROUND & AIMS: Diagnosis and surveillance of Barrett's esophagus (BE) and eosinophilic esophagit...
BACKGROUND: Early detection of oesophageal cancer improves outcomes; however, the optimal strategy f...
This multicentre, pragmatic, randomised controlled trial was done in 109 socio-demographically diver...
Background: Esophageal adenocarcinoma (EAC) accounts for an estimated 15 690 deaths in the US each y...
BACKGROUND: Barrett's esophagus (BE) is a commonly undiagnosed condition that predisposes to esophag...
Barrett's esophagus (BE) is a commonly undiagnosed condition that predisposes to esophageal adenocar...
BACKGROUND: Barrett's oesophagus predisposes to adenocarcinoma. However, most patients with Barrett'...
Abstract Background The Cytosponge is a cell-collection device, which, coupled with a test for trefo...
Barrett's esophagus (BE) is a commonly undiagnosed condition that predisposes to esophageal adenocar...
In the Perspective article in the March issue of Cellular and Molecular Gastroenterology and Hepatol...
DOI
Add to ORKG